Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus paclitaxel as neoadjuvant therapy for early triple-negative breast cancer
2014-003029-16Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing Ipatasertib + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Pathologic complete response rate in breast and axilla. Started Oct 2014; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2014-003029-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003029-16.